Investors
Category creation with institutional validation.
$400B TAM. Regulatory and clinical moats. A team that has shipped Class II devices before. Series B opening Q1 2027.
$50M
Series A raised
$400B
TAM (screening + monitoring + infra)
50K+
Consumer waitlist
12
Patents pending
Business model
- Hardware — $12K device (one-time)
- SaaS — $50/mo data platform
- B2B licensing — health systems, MedTech
Use of funds
- FDA approval — $5M
- Clinical trials — $15M
- Manufacturing — $20M
- Go-to-market — $10M
Request the investor deck
Gated. Accredited investors only.